Caribou Biosciences IncNASDAQ:CRBU
- LAST PRICE1.8212
- TODAY'S CHANGE (%)-0.0288 (-1.5568%)
- Bid / Lots1.8200/ 38
- Ask / Lots1.8300/ 24
- Open / Previous Close1.8500 / 1.8500
- Day Range
- 52 Week Range
- Volume303,074
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRBU |
|---|---|---|
| 09:32 ET | 30504 | 1.83 |
| 09:34 ET | 17424 | 1.83 |
| 09:36 ET | 50416 | 1.815 |
| 09:38 ET | 11448 | 1.82 |
| 09:39 ET | 300 | 1.825 |
| 09:41 ET | 604 | 1.8295 |
| 09:43 ET | 3237 | 1.82 |
| 09:45 ET | 3703 | 1.82 |
| 09:48 ET | 20854 | 1.825 |
| 09:50 ET | 3200 | 1.85 |
| 09:52 ET | 1480 | 1.84 |
| 09:54 ET | 300 | 1.83 |
| 09:56 ET | 1400 | 1.835 |
| 09:57 ET | 100 | 1.84 |
| 09:59 ET | 11194 | 1.83 |
| 10:01 ET | 373 | 1.835 |
| 10:03 ET | 5671 | 1.845 |
| 10:06 ET | 1200 | 1.84 |
| 10:08 ET | 300 | 1.84 |
| 10:10 ET | 13310 | 1.83 |
| 10:12 ET | 11654 | 1.83 |
| 10:14 ET | 800 | 1.85 |
| 10:15 ET | 625 | 1.85 |
| 10:19 ET | 6600 | 1.8471 |
| 10:21 ET | 100 | 1.845 |
| 10:24 ET | 349 | 1.845 |
| 10:26 ET | 425 | 1.85 |
| 10:28 ET | 7099 | 1.855 |
| 10:30 ET | 2008 | 1.845 |
| 10:32 ET | 500 | 1.85 |
| 10:33 ET | 3495 | 1.825 |
| 10:35 ET | 500 | 1.825 |
| 10:37 ET | 300 | 1.825 |
| 10:39 ET | 9622 | 1.81 |
| 10:42 ET | 4102 | 1.825 |
| 10:44 ET | 600 | 1.825 |
| 10:46 ET | 300 | 1.825 |
| 10:48 ET | 5277 | 1.825 |
| 10:50 ET | 335 | 1.824 |
| 10:51 ET | 431 | 1.8289 |
| 10:53 ET | 1102 | 1.82 |
| 10:55 ET | 2160 | 1.82 |
| 10:57 ET | 200 | 1.815 |
| 11:00 ET | 5363 | 1.82 |
| 11:02 ET | 1798 | 1.82 |
| 11:06 ET | 1200 | 1.815 |
| 11:08 ET | 100 | 1.82 |
| 11:09 ET | 3033 | 1.825 |
| 11:11 ET | 500 | 1.825 |
| 11:13 ET | 300 | 1.8299 |
| 11:15 ET | 400 | 1.8288 |
| 11:20 ET | 2216 | 1.815 |
| 11:22 ET | 6295 | 1.815 |
| 11:26 ET | 300 | 1.815 |
| 11:27 ET | 840 | 1.815 |
| 11:29 ET | 200 | 1.815 |
| 11:31 ET | 1033 | 1.815 |
| 11:33 ET | 100 | 1.81 |
| 11:36 ET | 1450 | 1.8199 |
| 11:38 ET | 400 | 1.815 |
| 11:40 ET | 200 | 1.815 |
| 11:42 ET | 3129 | 1.815 |
| 11:44 ET | 100 | 1.815 |
| 11:45 ET | 3622 | 1.825 |
| 11:47 ET | 246 | 1.8289 |
| 11:51 ET | 200 | 1.8212 |
Sep 25, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Caribou Biosciences Inc | 167.2M | -1.3x | --- |
Compugen Ltd | 155.8M | -16.2x | --- |
Cellectis SA | 151.3M | -1.0x | --- |
Mersana Therapeutics Inc | 230.6M | -2.2x | --- |
Nanobiotix SA | 231.3M | -4.1x | --- |
Elutia Inc | 129.8M | -1.3x | --- |
Company Information
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It is engaged in developing transformative therapies for patients with devastating diseases. Its genome-editing platform, including its Cas12a chRDNA technology, enables precision to develop cell therapies that are armored to potentially improve antitumor activity. Its pipeline includes three clinical-stage allogeneic cell therapies from its chimeric antigen receptor (CAR)-T (CAR-T) cell platform targeting the treatment of hematologic malignancies. CB-010 is the lead product candidate from its allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Its second product candidate, CB-011, is being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage phase I trial. CB-012 is its third product candidate.
Contact Information
- Headquarters
- 2929 7TH STREET, STE 120BERKELEY, CA, United States 94710
- Phone
- 510-982-6030
- Fax
- 302-531-3150
Executives
- Independent Chairman of the Board
- Andrew Guggenhime
- President, Chief Executive Officer, Co-Founder, Director
- Rachel Haurwitz
- Interim Principal Financial Officer and Interim Principal Accounting Officer
- Ryan Fischesser
- Chief People Officer
- Reigin Zawadzki
- Chief Technology Officer
- Tim Kelly
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $167.2M |
|---|---|
Revenue (TTM) | $33.1M |
Shares Outstanding | 90.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.39 |
Book Value | $4.17 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | 5.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -427.56% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
